BioPorto (2P4) Stock Overview
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2P4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.11 |
| 52 Week High | DKK 0.20 |
| 52 Week Low | DKK 0.10 |
| Beta | 1.23 |
| 1 Month Change | -6.06% |
| 3 Month Change | -18.80% |
| 1 Year Change | -42.59% |
| 3 Year Change | -63.40% |
| 5 Year Change | -85.98% |
| Change since IPO | -75.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2P4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.2% | 7.7% | 0.2% |
| 1Y | -42.6% | 3.8% | 2.1% |
Return vs Industry: 2P4 underperformed the German Biotechs industry which returned 3.8% over the past year.
Return vs Market: 2P4 underperformed the German Market which returned 2.1% over the past year.
Price Volatility
| 2P4 volatility | |
|---|---|
| 2P4 Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 2P4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2P4's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 48 | Carsten Buhl | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays.
BioPorto A/S Fundamentals Summary
| 2P4 fundamental statistics | |
|---|---|
| Market cap | €59.63m |
| Earnings (TTM) | -€11.61m |
| Revenue (TTM) | €4.89m |
Is 2P4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2P4 income statement (TTM) | |
|---|---|
| Revenue | DKK 36.56m |
| Cost of Revenue | DKK 13.20m |
| Gross Profit | DKK 23.36m |
| Other Expenses | DKK 110.16m |
| Earnings | -DKK 86.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 26, 2026
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 63.90% |
| Net Profit Margin | -237.40% |
| Debt/Equity Ratio | 0% |
How did 2P4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 03:11 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioPorto A/S is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Jyoti Prakash | Edison Investment Research |
| Yi Chen | H.C. Wainwright & Co. |